NCT05842239 Hyperbaric Oxygen Therapy for Men Suffering From Infertility Due to Oligospermia.
| NCT ID | NCT05842239 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assaf-Harofeh Medical Center |
| Condition | Oligospermia |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2024-01-20 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2024-01-20 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Infertility in a couple is defined as the inability to achieve conception despite one year of frequent, unprotected intercourse. Infertility affects approximately 12% of couples attempting to conceive. The goal of this study is to explore the potential beneficial effect of HBOT on sperm count of infertile male due to oligospermia.
Eligibility Criteria
Inclusion Criteria: 1. Age above 21 years 2. At least two sperm examination showing oligospermia (\<15·106 sperm/mL) 3. Diagnosis of idiopathic oligospermia. 4. Subject willing and able to read, understand and sign an informed consent Exclusion Criteria: 1. Inability to attend scheduled clinic visits and/or comply with the study protocol 2. Active malignancy 3. Previous treatment with chemotherapy and/or radiation therapy 4. Substance use at baseline 5. Severe or unstable physical disorders or major cognitive deficits at baseline 6. HBOT for any reason prior to study enrolment 7. Chest pathology incompatible with pressure changes (including moderate to severe asthma) 8. Ear or Sinus pathology incompatible with pressure changes 9. Chronic disease like diabetes mellitus, ischemic heart disease etc. 10. Active smoking
Contact & Investigator
Shachar Finci, MD
PRINCIPAL INVESTIGATOR
Asaf-Harofhe MC
Frequently Asked Questions
Who can join the NCT05842239 clinical trial?
This trial is open to male participants only, aged 21 Years or older, studying Oligospermia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05842239 currently recruiting?
Yes, NCT05842239 is actively recruiting participants. Contact the research team at shacharf@shamir.gov.il for enrollment information.
Where is the NCT05842239 trial being conducted?
This trial is being conducted at Ẕerifin, Israel.
Who is sponsoring the NCT05842239 clinical trial?
NCT05842239 is sponsored by Assaf-Harofeh Medical Center. The principal investigator is Shachar Finci, MD at Asaf-Harofhe MC. The trial plans to enroll 15 participants.